SALT LAKE CITY, December 29, 2025 — Co-Diagnostics announced that the Australian Patent Office has granted a key patent covering the Company’s Co-Dx PCR platform technologies, marking the first issued patent for its next-generation point-of-care PCR system. The newly granted patent strengthens Co-Diagnostics’ global intellectual property portfolio and provides broad protection for the design and operation of its PCR instrumentation, consumables, and system-level methods for nucleic acid detection outside traditional laboratory settings. The milestone supports the Company’s strategy to expand accurate, decentralized molecular diagnostics in regulated healthcare markets.
Science Significance
From a scientific standpoint, the patent underscores innovation in bringing laboratory-grade polymerase chain reaction (PCR) performance to point-of-care and decentralized environments. The protected technology covers system-level approaches that integrate instrument design, test cup architecture, and nucleic acid amplification workflows to maintain sensitivity and specificity typically associated with centralized labs. By leveraging proprietary primer and detection technologies, the Co-Dx PCR platform is designed to deliver gold-standard molecular accuracy in compact, user-friendly formats, enabling rapid infectious disease testing closer to patients. This represents a meaningful advance in translational diagnostics, where complex molecular science is engineered for real-world clinical and near-patient use.
Regulatory Significance
Regulatorily, the patent grant reinforces the Company’s long-term pathway toward regulated commercialization of point-of-care molecular diagnostics. While the Co-Dx PCR platform remains subject to regulatory review and is not yet approved for sale, strong intellectual property protection is a foundational requirement for navigating FDA and international regulatory frameworks. The patented system architecture supports future analytical validation, clinical performance studies, and quality system alignment, all of which are critical in GxP-regulated diagnostic environments. Securing IP in Australia also supports future regulatory filings and partnerships in jurisdictions with robust oversight of in vitro diagnostic devices.
Business Significance
Strategically, the Australian patent strengthens Co-Diagnostics’ competitive positioning in the global diagnostics market, particularly in the rapidly growing segment of decentralized and point-of-care molecular testing. Intellectual property protection enhances the Company’s ability to attract commercial partners, defend market share, and support regional distribution strategies. Australia represents a meaningful market for infectious disease diagnostics, and patent coverage provides a defensive and offensive business asset as the Company evaluates commercialization opportunities. The milestone also signals progress in executing a broader IP strategy designed to support long-term platform scalability across multiple assays and indications.
Patients’ Significance
For patients, the underlying technology has the potential to improve access to timely, accurate diagnostic testing, particularly in settings where centralized laboratory infrastructure is limited. Point-of-care PCR platforms can reduce diagnostic delays, improve clinical decision-making, and support faster initiation of appropriate care, especially during infectious disease outbreaks. Although the platform is still under regulatory review, the innovation reflected in the patent aligns with broader healthcare goals of bringing high-quality diagnostics closer to patients, improving equity, and supporting rapid response in community and outpatient environments.
Policy Significance
At a policy level, the patent grant highlights the importance of intellectual property protection in sustaining innovation within regulated healthcare technologies. Governments and health systems increasingly recognize the role of advanced diagnostics in public health preparedness, surveillance, and outbreak response. Strong IP frameworks encourage private-sector investment in complex, high-risk technologies such as molecular diagnostics, while enabling collaboration with public health agencies and healthcare providers. The development of decentralized PCR platforms also aligns with policy priorities aimed at strengthening diagnostic capacity beyond hospital laboratories.
In summary, Co-Diagnostics’ receipt of an Australian patent for its Co-Dx PCR platform represents a significant technological and strategic milestone, reinforcing the Company’s commitment to advancing next-generation molecular diagnostics. By securing international intellectual property protection for its point-of-care PCR system, Co-Diagnostics strengthens its foundation for future regulatory progress, commercialization, and global expansion. As demand for accurate, decentralized diagnostics continues to grow, the patent positions the Company to play a meaningful role in shaping the future of molecular testing in regulated healthcare environments.
Source: Co-Diagnostics press release


